Drug Interactions of Eplerenone
Eplerenone has clinically significant interactions primarily through CYP3A4 metabolism, with strong CYP3A4 inhibitors being contraindicated and requiring careful dose adjustments with moderate inhibitors, plus important hyperkalemia risks when combined with other potassium-elevating medications.
Critical CYP3A4-Mediated Interactions
Strong CYP3A4 Inhibitors (CONTRAINDICATED)
Do not use eplerenone with strong CYP3A4 inhibitors 1, 2. These drugs can increase eplerenone levels dramatically:
- Antifungals: ketoconazole (increases AUC 5.4-fold), itraconazole
- Antivirals: ritonavir, nelfinavir, atanazavir, saquinavir
- Antibiotics: clarithromycin, telithromycin
- Other: nefazadone, nicardipine
A case report documented severe life-threatening hyperkalemia in an HIV-positive patient taking ritonavir-boosted fosamprenavir with eplerenone, requiring 2 weeks to normalize potassium despite aggressive treatment 3.
Moderate CYP3A4 Inhibitors (DOSE REDUCTION REQUIRED)
Limit eplerenone to maximum 25 mg daily when combined with moderate CYP3A4 inhibitors 1, 2. These increase eplerenone AUC by 100-190%:
- Macrolides: erythromycin
- Calcium channel blockers: verapamil, diltiazem
- Antifungals: fluconazole
- Antivirals: saquinavir
- Antiarrhythmics: amiodarone
- Food: grapefruit juice (25% increase in exposure)
CYP3A4 Inducers (TREATMENT FAILURE RISK)
Strong CYP3A4 inducers reduce eplerenone AUC by up to 30%, potentially causing treatment failure 1:
- St. John's wort (millepertuis)
- Rifampicin
- Carbamazepine
- Phenytoin
- Phenobarbital
Important caveat: Trimethoprim is both a CYP3A4 inducer AND increases hyperkalemia risk independently—requires close monitoring of potassium and renal function, especially in elderly patients 1.
Hyperkalemia-Potentiating Interactions
High-Risk Combinations (Use with Extreme Caution)
ACE Inhibitors and ARBs: Exercise caution when combining eplerenone with these agents due to additive hyperkalemia risk, particularly in patients with renal impairment, elderly patients, or those with diabetes 1. Close surveillance of potassium and renal function is mandatory.
Cyclosporine and Tacrolimus: These combinations should be avoided if possible due to dual mechanisms of hyperkalemia (impaired renal function plus potassium retention) 1. If unavoidable, monitor potassium and renal function very closely.
Lithium: Avoid this combination 1. While no formal interaction studies exist for eplerenone-lithium, lithium toxicity has been reported with other diuretics and ACE inhibitors. If combination is unavoidable, monitor plasma lithium concentrations closely.
Heparin (including LMWH): In patients with kidney failure, heparin combined with eplerenone may induce hyperkalemia 1.
Cardiovascular Drug Interactions
Digoxin: Eplerenone increases digoxin AUC by 16% (90% CI: 4-30%) 1. Exercise caution if digoxin levels are near the upper therapeutic limit; monitor for signs of digitalis toxicity.
Warfarin: Use caution if warfarin levels are near the upper therapeutic limit 1. However, no clinically significant pharmacokinetic interactions were observed in formal studies 2.
Alpha-blockers (prazosin, alfuzosin): May increase hypotensive effect and induce orthostatic hypotension 1. Monitor for orthostatic hypotension clinically when combining these agents.
Tricyclic antidepressants, neuroleptics, amifostine, baclofen: Risk of increased antihypertensive effect and orthostatic hypotension 1.
Drugs That Reduce Eplerenone Efficacy
Glucocorticoids and tetracosactide: May reduce antihypertensive effect through salt and water retention 1.
NSAIDs: May cause acute kidney failure by direct impact on glomerular filtration, especially in elderly or dehydrated patients 1. Ensure adequate hydration and check renal function before initiating combination therapy.
Drugs WITHOUT Significant Interactions
Eplerenone does NOT significantly interact with 2:
- Cisapride
- Cyclosporine (pharmacokinetically—though hyperkalemia risk remains)
- Glyburide
- Midazolam
- Oral contraceptives (norethindrone/ethinyl estradiol)
- Simvastatin
- Aluminum/magnesium-containing antacids
Key Monitoring Recommendations
When initiating eplerenone or adding interacting medications:
Measure serum potassium and renal function within 2-3 months of starting therapy 4
More frequent monitoring needed in patients with:
- Prior severe hypokalemia
- Renal impairment (especially GFR <60 mL/min)
- Diabetes
- Elderly patients
- Those on multiple interacting medications
Consider discontinuing potassium supplements at days 2-4 of eplerenone initiation in most patients (except severe hypokalemia cases) 4
Special Populations
Renal impairment: Use eplerenone with caution in stage III chronic kidney disease (GFR <60 mL/min/1.73 m²); avoid in stage IV disease 5.
Pregnancy: Category B—no teratogenic effects in animal studies, though some fetal effects observed at high doses 1.